Taimour Langaee - Concepedia

Author

Taimour Langaee

Also Known As

Langaee, Taimour, Misher, Anne, Nathan Pankratz, Pankratz, Nathan, T LANGAEE, T Langaee, T Y Langaee, T. Langaee, T. Y. Langaee, T.Y. LANGAEE

200

Publications

8.5K

Citations

H-Index

148

Concepts

All Affiliations

University of Florida Florida College Emory University University of Florida Health American Association of Colleges of Pharmacy

About

Taimour Langaee is an author at University of Florida specializing in medicine, pharmacology, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	40	2.5K
2	Public Health	10	10	626
3	Health Sciences	7	7	395
4	Education	2	2	194
5	Natural Sciences	2	2	85

Taimour Langaee

100

Publications

6.9K

Citations

H-Index

Page 1

	Year	Citations
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin Charles Eby, JA Johnson, Elena Deych, Clinical Pharmacology & Therapeutics	2008	829
CYP4F2 genetic variant alters required warfarin dose Michael D. Caldwell, Tarif Awad, Julie A. Johnson, Blood	2008	519
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose Gregory M. Cooper, Julie A. Johnson, Taimour Langaee, Blood	2008	485
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study Minoli A. Perera, Larisa H. Cavallari, Nita A. Limdi, The Lancet Genome-wide Association StudyThrombosisGenetic VariantsEpidemiologyAllelic Variant	2013	272
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements Christina L. Aquilante, Taimour Langaee, Lucy E. Correa-López, Clinical Pharmacology & Therapeutics	2006	270
Two CES1 Gene Mutations Lead to Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular Basis Hao‐Jie Zhu, Kennerly S. Patrick, Hong-Jie Yuan, The American Journal of Human Genetics GeneticsMolecular BiologyDysfunctional Carboxylesterase 1PathologyMolecular Basis	2008	220
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors Erin Dunbar, Bonnie S. Coats, Albert L. Shroads, Investigational New Drugs Neuro-oncologyMedicineMetronomic TherapyNeurologyHigh-grade Gliomas	2013	217
Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans Larisa H. Cavallari, Taimour Langaee, Kathryn M. Momary, Clinical Pharmacology & Therapeutics	2010	199
Clinical pharmacogenetics implementation: Approaches, successes, and challenges Kristin Weitzel, Amanda R. Elsey, Taimour Langaee, American Journal of Medical Genetics Part C Seminars in Medical Genetics Uf PmpPercutaneous Coronary InterventionTranslational MedicineClinical Pharmacogenetics ImplementationCardiovascular Disease	2014	188
CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial D. Max Smith, Kristin Weitzel, Amanda R. Elsey, Genetics in Medicine Molecular PharmacologyPain ResearchPain TherapyHealth SciencesCyp2d6 Intermediate	2019	150

Page 1